Serum Institute of India
Indian biotechnology and biopharmaceuticals company
Serum Institute of India ▸ Facts ▸ Comments ▸ News ▸ Videos
Serum Institute of India (SII) is an Indian biotechnology and biopharmaceuticals company, based in Pune. It was founded by Cyrus Poonawalla in 1966 and is a part of Cyrus Poonawalla Group.
| 0 shares | ShareTweetSavePostSend |
You Might Like
1 in 3 Covaxin recipients hit by adverse events: StudyNearly one-third of Covaxin recipients experienced adverse events of special interest within a year, including respiratory, skin, and musculoskeletal issues. The study also highlighted menstrual..IndiaTimes - Published | |
Stopped producing Covishield in Dec 2021: SII after AstraZeneca recallUK-based drug major AstraZeneca's decision to withdraw its Covid-19 vaccine globally, days after admitting to side effects, prompted Serum Institute of India to disclose that it had stopped..IndiaTimes - Published | |
Age is just a number, look at Ratan Tata, Bachchan: NCP Lok Sabha member Supriya Sule takes on Ajit Pawar"Some people are saying that people who are senior now should give us their blessings (and retire). Why should they stop working? Ratan Tata who heads India's largest conglomerate is 86 years old...IndiaTimes - Published | |
Content posted against Serum Institute of India, its Covishield vaccine prima facie defamatory: Bombay HCThe Bombay high court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and..IndiaTimes - Published | |
'Elderly people can...': SII's CEO Adar Poonawalla's big remark on Covid spike in IndiaIndia has recorded 12,193 fresh Covid-19 cases in 24 hours. The number of active cases climbed to 67,556.DNA - Published | |
Covovax for adults to reach metros in a week: SIISerum Institute of India’s CEO Adar Poonawalla told TOI on Friday that doses of Covovax — Covid booster shot for adults — would reach major cities in four to five days, while a Bharat Biotech..IndiaTimes - Published | |
SII to restart vaccine production amid surge in Covid casesSerum Institute of India CEO Adar Poonawalla told TOI on Wednesday that the company has resumed production of its Covid-19 vaccine, Covishield, in response to the increasing number of SARS-CoV-2 virus..IndiaTimes - Published | |
Serum Institute of India restarts manufacturing of Covid-19 vaccine CovishieldSerum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of Covid-19 vaccine Covishield amid rising numbers of cases of the virus infection. He said the..IndiaTimes - Published | |
Serum Institute seeks inclusion of Covovax on CoWIN as heterologous booster dose for adultsIndiaTimes - Published | |
India well-prepared to combat any future waves: SII CEO Adar Poonawalla amid Covid scare in ChinaIndiaTimes - Published | |
Drug panel favours nod for Covovax as Covid boosterAn expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India’s Covid vaccine, Covovax, as a heterologous booster dose for adults who have..IndiaTimes - Published | |
Covovax may get approval as heterologous boosterThe government may decide on allowing Serum Institute of India’s (SII) Covovax as a heterologous booster dose, meaning it can be used for people who have taken either Covishield or Covaxin for..IndiaTimes - Published | |
Covovax vaccine to get booster dose approval in 10-15 days: SII CEO Adar PoonawallaIndiaTimes - Published | Covid situation in India better than elsewhere: SII CEO Adar PoonawallaSerum Institute CEO Adar Poonawalla on Sunday lauded India's fight against the Covid pandemic, saying the government and the healthcare workers contributed largely to tackling the pandemic. "Everyone..IndiaTimes - Published |
Serum Institute to provide 2 crore Covishield doses to central govt free of costIndiaTimes - Published | News of rising covid cases coming out of China is concerning: Adar PoonawallaCovid has made a comeback in China and the world is worried about its spread. Adar Poonawalla of the SII has spoken about it.DNA - Published |
HPV vaccine production delayed due to Covid focus, will start supply to Indian govt in early 2023: SIISerum Institute of India (SII) had to defer HPV vaccine production by two years due to the focus on Covid, and will start supplying small quantities of the dose to the Indian government in early 2023,..IndiaTimes - Published | SII's Adar Poonawalla makes clarion call for global certification of vaccines"Multilateral organisations such as the United Nations and the World Trade Organisation should take it upon themselves to harmonise the certification of vaccines," Adar Poonawalla told PTI on the..IndiaTimes - Published |
Scammers send fake message in CEO Adar Poonawalla's name, dupe Serum Institute of Rs 1 croreFraudsters allegedly attempted to con one of SII's directors by sending him a WhatsApp message asking him to wire money to numerous other accounts.DNA - Published | Fraudsters dupe Serum Institute of Rs 1 cr by asking for money transfer in CEO's nameIndiaTimes - Published |
Bombay HC issues notice to Central govt, Bill Gates, Serum Institute over plea on alleged Covid vaccine deathIndiaTimes - Published | Cost of cervical cancer vaccine set to be Rs 200-400Cervavac, India's first indigenously developed vaccine for preventing cervical cancer caused by Human Papilloma Virus (HPV), is likely to be priced between Rs 200-400 per dose, Serum Institute of India..IndiaTimes - Published |
SII will try to launch Omicron-specific vaccine after six months: Adar PoonawallaIndiaTimes - Published Also reported by •DNA | Desi qHPV vaccine against cervical cancer to be launched todayIndia is all set to launch on Thursday its first indigenously developed quadrivalent Human Papilloma Virus (HPV) vaccine for prevention of cervical cancer. It has been developed by the Serum Institute..IndiaTimes - Published |
Vaccine for Omicron likely in 6 months: SII’s PoonawalaThe vaccine will be specific to the BA5 sub-variant of the Omicron strain, SII CEO Adar Poonawalla told a TV channel, adding that he thought “this vaccine is important as a booster”.IndiaTimes - Published | SII CEO meets Mandaviya to discuss research on possible monkeypox vaxIndiaTimes - Published |
Serum Institute of India to launch indigenously made vaccine to treat cervical cancerSerum Institute of India CEO Adar Poonawalla on Tuesday said the company plans to launch its indigenously-developed vaccine to treat cervical cancer in women later this year.IndiaTimes - Published | SII gets govt nod to export 32.4 lakh doses of Covovax vaccine to USThe government has allowed Serum Institute of India (SII) to supply 32.4 lakh doses of its Covid-19 jab Covovax under the brand name Nuvaxovid to the US, which will be the first vaccine to be exported..IndiaTimes - Published |
Covid-19 vaccine: SII's Covovax gets nod for emergency use in children aged 7 to 11 yearsThe DCGI had approved Covovax for restricted emergency use in adults on December 28, 2021, and in 12-17 years age group on March 9, 2022.DNA - Published | Govt panel recommends emergency approval for SII's Covovax for 7-11 year oldsAn expert panel of India's central drug authority on Friday recommended granting emergency use authorisation to Serum Institute's Covovax for children aged 7 to 11 years, official sources said. The..IndiaTimes - Published |
Covid-19 vaccine: SII significantly lowers price of each dose of CovovaxThis comes a day after Covovax was included on the CoWIN portal for inoculation of children aged 12-17 years at private vaccination centres.DNA - Published | Covid-19 vaccine Covovax now available for children in India: Adar PoonawallaSerum Institute of India (SII) CEO Adar Poonawalla on Tuesday said that the Covid-19 vaccine Covovax is now available in India for children. He also hailed PM Narendra Modi for his vision of providing..IndiaTimes - Published |
Govt unlikely to procure SII’s Covovax for 12-17 age groupAs majority of youngsters has already taken the first dose of Covid vaccine, the government is unlikely to procure Serum Institute of India’s Covovax for use in adolescents of 12-17 years under the..IndiaTimes - Published | NTAGI panel recommends inclusion of Covovax in inoculation drive for 12-17 age groupSerum Institute of India (SII) Director for Government and Regulatory Affairs Prakash Kumar Singh had written to the Union Health Ministry recently, rDNA - Published |
Covid-19: Serum Institute of India halts vaccine production over millions of unused dosesSerum Institute of India Ltd., the world’s largest vaccine manufacturer and a key supplier of Covid-19 inoculations to developing countries, has stopped making fresh batches of shots after its..IndiaTimes - Published | Reduce time gap for Covid vaccine booster dose to six months: Serum Institute to govtVaccine major Serum Institute of India (SII) has appealed to the government to reduce the gap between the second and booster dose to six months from nine months at present to safeguard people against..IndiaTimes - Published |
Bharat Biotech, SII slash prices of Covaxin, Covishield booster dose to Rs 225 per shotIndiaTimes - Published | Covishield, Covaxin prices slashed ahead of booster drive expansionSerum Institute of India has reduced the price of its Covishield vaccine from Rs 600 to Rs 225 per dose for private hospitals, the vaccine maker announced on Saturday. Bharat Biotech also slashed the..IndiaTimes - Published |
Serum Institute of India prices Covishield booster dose at Rs 600SII CEO Adar Poonawalla also welcomed the government's move to allow precautionary doses of the vaccine to all aged above 18 years.DNA - Published | Serum Institute's Covishield precaution dose priced at Rs 600 per shotVaccine maker Serum Institute of India (SII) on Friday said the precaution dose of its Covishield vaccine against Covid-19 will be priced at Rs 600 per shot for eligible individuals.IndiaTimes - Published |
SII’s Covovax for those aged 12+ gets panel nodThe Covid-19 working group under the government’s vaccine advisory body has recommended use of the Serum Institute of India’s Covovax in the national vaccination programme for those aged 12 years..IndiaTimes - Published | Novavax says its Covid vaccine gets India authorisation for adolescentsNovavax Inc on Tuesday said that the Drugs Controller General of India (DCGI) has granted emergency use authorisation for its Covid-19 vaccine for adolescents aged 12 to 17 in the country. The..IndiaTimes - Published |
Covid-19: Covovax gets DCGI’s EUA nod for 12-17-year-oldsIn a move that will further expand the basket of Covid vaccines approved for adolescents, the drug regulator has given emergency approval to Serum Institute of India’s Covovax for use in 12-17 year..IndiaTimes - Published | DCGI's EUA nod to Covovax for 12-17 years age groupIndia's drug regulator has granted restricted emergency use authorisation to Serum Institute of India's COVID-19 vaccine Covovax for the 12-17 years age group subject to certain conditions, official..IndiaTimes - Published |
Covid-19: SII's Covovax vaccine recommended for Phase 3 trial as booster dose in adultsThe Pune-based SII had sought the permission from the DCGI to conduct Phase 3 study to evaluate the safety and immunogenicity of Covovax.DNA - Published | Government panel recommends EUA for Covid vaccine Covovax for 12-17 age groupPrakash Kumar Singh, director-government and regulatory affairs at Serum Institute of India (SII), had submitted an application to the DCGI on February 21, seeking EUA for Covovax for the 12 to 17..IndiaTimes - Published |
SII seeks permission for Covovax vaccine phase-3 study of booster dose in adultsThe Drugs Controller General Of India (DCGI) had approved Covovax for restricted use in emergency situations in adults on December 28.DNA - Published | 230 kids aged 2-6 become youngest to get Covid jabs in Covovax trialA group of 230 children aged two to six have become the youngest in the country to get a Covid vaccine after they were given at least one dose during trials of the Covovax jab, manufacturer Serum..IndiaTimes - Published |
SII makes available vaccines at price of 'cup of tea' to poor nations, says Cyrus PoonawallaIndiaTimes - Published | Serum Institute has applied for full market authorisation of Covishield: CEO Adar PoonawalaSerum Institute has applied to the Indian health ministry and Central Drugs Standard Control Organisation (CDSCO) for full market authorisation for its Covishield vaccine, company's CEO Adar Poonawalla..IndiaTimes - Published |
